Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:AMYT Amryt Pharma (AMYT) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About Amryt Pharma Stock (NASDAQ:AMYT) 30 days 90 days 365 days Advanced Chart Ad Priority GoldJD Vance Predicts: Wall Street vs. Trump & Your MoneyTrump's back in the White House, but Wall Street is pissed. Here's the deal: Wall Street's about to purposely crash the bond market to sabotage Trump's comeback.Get your free guide NOW before it's too late. Get Amryt Pharma alerts:Sign Up Key Stats Today's Range$14.63▼$14.7650-Day Range$14.55▼$14.7052-Week Range$6.41▼$14.77Volume2.39 million shsAverage Volume757,360 shsMarket Capitalization$940.21 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewAmryt Pharma plc, a commercial-stage biopharmaceutical company, focuses on acquiring, developing, and commercializing various treatments to help improve the lives of patients with rare and orphan diseases. The company provides metreleptin, an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy; oral octreotide, a long-term maintenance therapy in acromegaly patients; and lomitapide, an adjunct to a low-fat diet and other lipid-lowering medicinal products for adults with the Homozygous familial Hypercholesteraemia. Its development candidates include Oleogel-S10 for the cutaneous manifestations of Junctional and Dystrophic Epidermolysis Bullosa (EB), a rare and distressing genetic skin disorder affecting young children and adults; and AP103, a pre-clinical gene therapy for patients with dystrophic EB. The company sells its products in the Americas, Europe, and the Middle East. Amryt Pharma plc was founded in 2015 and is headquartered in Dublin, Ireland.Read More… JD Vance Predicts: Wall Street vs. Trump & Your Money (Ad)Trump's back in the White House, but Wall Street is pissed. Here's the deal: Wall Street's about to purposely crash the bond market to sabotage Trump's comeback.Get your free guide NOW before it's too late. Receive AMYT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Amryt Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address AMYT Stock News HeadlinesAlembic Pharmaceuticals Ltd.October 13, 2023 | wsj.comAMYT Historical DataOctober 10, 2023 | investing.comTop secret Trump trades?As you likely know, the “Trump bump” launched stocks to record highs after he secured his second reelection bid. Now, Trump and his team are coming to gut government regulation – and it’s going to create some incredible market opportunities. But while the masses chase large-cap tech and so-called AI stocks, a small circle of traders are using a strange but tactical method to find a pool of “hidden Trump trades.”November 27, 2024 | Insiders Exposed (Ad)Beijing Sun-Novo Pharmaceutical Research Co. Ltd. AJuly 28, 2023 | wsj.com2022 for Chiesi: The Group’s international growth continuesApril 11, 2023 | finance.yahoo.comHigh Court of Justice of England and Wales Sanctions Scheme of ArrangementApril 3, 2023 | finance.yahoo.comAmryt Pharma Stock (NASDAQ:AMYT), DividendsMarch 17, 2023 | benzinga.comAMRYT PUBLISHES SCHEME CIRCULAR AND ANNOUNCES THE SHAREHOLDER MEETINGS TO CONSIDER AND VOTE ON THE CHIESI ACQUISITION WILL BE HELD ON MARCH 22, 2023February 16, 2023 | finance.yahoo.comSee More Headlines AMYT Stock Analysis - Frequently Asked Questions How were Amryt Pharma's earnings last quarter? Amryt Pharma plc (NASDAQ:AMYT) announced its quarterly earnings data on Thursday, November, 5th. The company reported ($0.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.73) by $0.66. The business earned $49.33 million during the quarter. Amryt Pharma had a positive trailing twelve-month return on equity of 1.70% and a negative net margin of 8.19%. What other stocks do shareholders of Amryt Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Amryt Pharma investors own include Alibaba Group (BABA), Dynavax Technologies (DVAX), Advanced Micro Devices (AMD), Teladoc Health (TDOC), NIO (NIO), Block (SQ) and Tesla (TSLA). Company Calendar Last Earnings11/05/2020Today11/27/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:AMYT CUSIPN/A CIK1783010 Webwww.amrytpharma.com Phone353-1518-0200FaxN/AEmployees2,020Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.06) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$1 million Net Margins-8.19% Pretax Margin-0.56% Return on Equity1.70% Return on Assets0.75% Debt Debt-to-Equity Ratio0.64 Current Ratio1.57 Quick Ratio0.94 Sales & Book Value Annual Sales$222.54 million Price / Sales4.22 Cash Flow$0.98 per share Price / Cash Flow14.98 Book Value$5.58 per share Price / Book2.63Miscellaneous Outstanding Shares63,960,000Free Float60,343,000Market Cap$940.21 million OptionableNot Optionable Beta0.84 A Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free Report This page (NASDAQ:AMYT) was last updated on 11/27/2024 by MarketBeat.com Staff From Our PartnersBill Gates’ is about to mint millionaires (again) with Stargate.This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredDeFi Coin on Verge of Breakout!The blueprint for millionaires is here. Don't let this be the missed opportunity you regret for years. Crypto 101 Media | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amryt Pharma plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Amryt Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.